Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

In Liverpool, the use of NHS concentrate increased in 1983.

  • Read more about In Liverpool, the use of NHS concentrate increased in 1983.

At a Mersey RTC meeting, there was no discussion at all about the issue of AIDS.

  • Read more about At a Mersey RTC meeting, there was no discussion at all about the issue of AIDS.

Small amounts of cryoprecipitate were used with NHS concentrate and commercial concentrates were used in substantial amounts at the Leeds Haemophilia Centre.

  • Read more about Small amounts of cryoprecipitate were used with NHS concentrate and commercial concentrates were used in substantial amounts at the Leeds Haemophilia Centre.

1,497,585 units of NHS Factor 8 and 1,715,894 units of commercial concentrates were used at the Leeds Haemophilia Centre.

  • Read more about 1,497,585 units of NHS Factor 8 and 1,715,894 units of commercial concentrates were used at the Leeds Haemophilia Centre.

Whilst the volume of NHS concentrate used at the Leeds Haemophilia Centre increased in 1983, a very substantial amount of commercial concentrate continued to be used.

  • Read more about Whilst the volume of NHS concentrate used at the Leeds Haemophilia Centre increased in 1983, a very substantial amount of commercial concentrate continued to be used.

Dr Colvin reported that, at London Hospital Haemophilia Centre, there were 41 patients infected with HIV, of whom 31 had severe Haemophilia A, 9 had moderate/mild Haemophilia A and 1 had Haemophilia B. He recalled three children who were infected with HIV from their treatment and one partner of a patient who was infected.

  • Read more about Dr Colvin reported that, at London Hospital Haemophilia Centre, there were 41 patients infected with HIV, of whom 31 had severe Haemophilia A, 9 had moderate/mild Haemophilia A and 1 had Haemophilia B. He recalled three children who were infected with HIV from their treatment and one partner of a patient who was infected.

It was stated that "until a positive test for AIDS and/or a vaccine is developed it should be policy to avoid use of blood products except for essential treatments and to use cryoprecipitate or plasma instead of FVIII Concentrate whenever possible."

  • Read more about It was stated that "until a positive test for AIDS and/or a vaccine is developed it should be policy to avoid use of blood products except for essential treatments and to use cryoprecipitate or plasma instead of FVIII Concentrate whenever possible."

Dr Colvin wrote that they knew little about AIDS at this time. The health service should not "spurn" commercial concentrate as they must stay aware of the risks associated with NHS material.

  • Read more about Dr Colvin wrote that they knew little about AIDS at this time. The health service should not "spurn" commercial concentrate as they must stay aware of the risks associated with NHS material.

In reference to the risks of AIDS in haemophilia services, possible complications in treatment were described as "Plasma product-transmitted disease, particularly hepatitis and (possibly) the acquired immune deficiency syndrome (AIDS)"

  • Read more about In reference to the risks of AIDS in haemophilia services, possible complications in treatment were described as "Plasma product-transmitted disease, particularly hepatitis and (possibly) the acquired immune deficiency syndrome (AIDS)"

A reduction in the purchase of commercial concentrate in 1983 was due to an increase in supply of NHS material demonstrating Dr Colvin's intent to minimise risk where and when it was sensible to do so.

  • Read more about A reduction in the purchase of commercial concentrate in 1983 was due to an increase in supply of NHS material demonstrating Dr Colvin's intent to minimise risk where and when it was sensible to do so.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Current page 34
  • Page 35
  • Page 36
  • Page 37
  • Page 38
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.